Meyeon Park, MD
Nephrology · San Francisco, CANPI 1508041187
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $112,799 of the $119,326 with a category attached, or 94.5%. 6 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 56.6% of the total. 2024 is the largest year on record at $52,657, 5.7 times the $9,270 reported in 2019. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1510.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$67K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$32K
- Vertex$18K
- Sanofi$2K
- Amgen$111
- Mallinckrodt Enterprises LLC$100
Across 28 payments — averaging $39,894 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kadmon Corporation LLC$458K
- Vertex$261K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$231K
- Sanofi$67K
- AbbVie$47K
- Biogen$31K
- plus $23K from 2 others
What the payments were for
- Consulting fees$112,79995%
- Travel & lodging$5,1674%
- Food & beverage$1,2601%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 48 | $67,480 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 17 | $31,588 |
| Vertex | 11 | $17,955 |
| Sanofi | 1 | $2,092 |
| Amgen | 1 | $111 |
| Mallinckrodt Enterprises LLC | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,326 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $418 |
| Carvedilol | 22 | $150 |
| Lisinopril | 18 | $143 |
| Atorvastatin Calcium | 15 | $71 |
| Losartan Potassium | 13 | $28 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Francisco
- Raymond HsuSan Francisco$77K
- Fred LuiSan Francisco$68K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.